Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Arrowhead Pharmaceuticals Corp (ARWR) Tops Q2 EPS by 5c
May 8, 2019 4:01 PM EDTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q2 EPS of $0.24, $0.05 better than the analyst estimate of $0.19. Revenue for the quarter came in at $48.15 million versus the consensus estimate of $42.99 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
... More